Christopher Vallorosi, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 45.2% of the total. Reporting peaked in 2024 at $3,281 and has fallen 86.2% since, to $453 in 2025.
Across 160 payments — averaging $42.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$3K
- Boston Scientific$1K
- AbbVie$295
- Laborie Medical Technologies Corp.$161
- Rochester Medical Corporation$158
- Urovant Sciences Inc$147
- plus $2K from 30 others
What the payments were for
- Consulting fees$2,31034%
- Speaking & faculty fees$1602%
- Travel & lodging$93414%
- Food & beverage$3,22048%
- Education$1032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 38 | $3,039 |
| Boston Scientific | 10 | $1,283 |
| AbbVie(2 entities) | 14 | $295 |
| Laborie Medical Technologies Corp. | 3 | $161 |
| Rochester Medical Corporation | 3 | $158 |
| Urovant Sciences Inc | 14 | $147 |
| Progenics Pharmaceuticals, Inc. | 6 | $142 |
| Bayer | 7 | $138 |
| Johnson & Johnson | 8 | $131 |
| Neotract Inc. | 2 | $129 |
| Pfizer | 7 | $101 |
| Urogen Pharma, Inc. | 4 | $97 |
| Merck | 5 | $93 |
| Astellas Pharma US Inc | 5 | $81 |
| Tolmar, Inc. | 3 | $79 |
| Intuitive Surgical | 1 | $77 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $70 |
| Baxter Healthcare | 3 | $53 |
| Olympus America Inc. | 2 | $41 |
| Ferring Pharmaceuticals Inc. | 2 | $39 |
| Bioprotect Medical, Inc. | 2 | $37 |
| Myovant Sciences Inc. | 2 | $36 |
| Procept Biorobotics Corporation | 1 | $33 |
| Bluewind Medical | 1 | $31 |
| Immunitybio, Inc. | 1 | $28 |
| Axonics, Inc. | 1 | $27 |
| Coloplast | 2 | $26 |
| Endo Pharmaceuticals Inc. | 2 | $24 |
| Blue Earth Diagnostics | 1 | $23 |
| Amgen | 1 | $19 |
| 180 Medical, Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Calyxo, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $13 |
| Myriad Genetic Laboratories, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,728 in reported general payments places this provider in the 80th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 37 | $608,063 |
| XtandiEnzalutamide | 28 | $395,956 |
| MyrbetriqMirabegron | 368 | $377,787 |
| OrgovyxRelugolix | 98 | $269,621 |
| GemtesaVibegron | 206 | $228,554 |
| NubeqaDarolutamide | 14 | $197,096 |
| Finasteride | 1,518 | $30,125 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 176 | $28,723 |
| Tamsulosin Hcl | 1,424 | $25,725 |
| Oxybutynin Chloride ErOxybutynin Chloride | 556 | $19,301 |
| Silodosin | 121 | $17,361 |
| Testosterone | 53 | $12,577 |
| Dutasteride | 191 | $9,434 |
| Solifenacin Succinate | 132 | $7,418 |
| Estradiol | 33 | $6,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $81 | $773,743396 claims |
| Johnson & JohnsonErleada | $131 | $608,06337 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $3,039 | $498,176304 claims |
| BayerNubeqa | $138 | $197,09614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 urology providers in Delaware.
Other urology in Dover
- Joohyong KimDover$7K
- Michael ZaragozaDover$6K
- Gregory SpanaDover$5K
- Raj KurpadDover$3K
- Donald SuhDover$2K
- Jason WaltherDover$87
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Thomas DesperitoWilmington$7K
- Raymond BolognaMilford$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.